What is Unity Biotechnology 12-1 Month Momentum %?
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2025-03-04), Unity Biotechnology's 12-1 Month Momentum % is 20.56%.
The industry rank for Unity Biotechnology's 12-1 Month Momentum % or its related term are showing as below:
UBX's 12-1 Month Momentum % is ranked better than 79.05% of 1446
companies
in the Biotechnology industry
Industry Median: -23.3
vs UBX: 20.56
Competitive Comparison of Unity Biotechnology's 12-1 Month Momentum %
For the Biotechnology subindustry, Unity Biotechnology's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Unity Biotechnology's 12-1 Month Momentum % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Unity Biotechnology's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Unity Biotechnology's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Unity Biotechnology 12-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of Unity Biotechnology's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
UBX has been successfully added to your